Last year, there was a lot of positive press about Alzhemed, a possible new treatment for Alzheimer's. At the time, a Phase 2 study showed "that overall, approximately 70% of the mild AD patients had stabilized or improved cognitive function tests even after 20 months of enrollment in the Alzhemed open-label Phase II extension study."
Well this week, some Wall Street analysts suspect Neurochem's (the company that is developing Alzhemed) recently issued $80 million in convertible notes and warrants is an indication the company's unreleased phase 3 trial of its Alzheimer's treatment Alzhemed yielded disappointing results.
Comments